

SARS-CoV-2 Spike S1 protein [Expressed in HEK293 cell]

Origin:	Recombinant
Source:	HEK293
Tag:	His at C-terminus
Cat No.	41A230
Size:	100 μg
Purity:	>95%
Endotoxin:	<5 EU/mg, determined by the
LAL method	

Introduction to the molecule

The spike (S) glycoprotein of SARS-CoV-2, which is highly exposed on the viral surface, plays a major role in inducing neutralizing antibody, T cell responses and protective immunity. The S protein contains two subunits: S1 and S2 cleaved by furin in host cells. S1 mediates the interaction of SARS-CoV-2 to the host cell receptor (ACE2) through its receptor-binding domain and is the target of vaccine development.

Product information

The recombinant SARS-CoV-2 Spike S1 Protein (YP_009724390.1) (Val16-Arg685) with C-terminal His-tag consists of 681 amino acids. Its predicted molecular mass of 681 amino acids. Its predicted molecular mass of 77 kDa. The apparent molecular mass of S1 in SDS-PAGE is around 120 kDa, probably due to glycosylation. The concentration of protein was determined by BCA.



Bioactivity & antigenicity: Strong binding ability with human ACE2 protein and binding capacity to a human anti-S1 monoclonal antibody (determined by ELISA).



Formulation and storage: Lipid in PBS, PH7.4. Store at -80°C. Recommend to aliquot the protein into smaller quantities. Avoid repeated freeze-thaw cycles.

Reference

- Shajahan A, et al. (2020) Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. bioRxiv, <u>https://doi.org/10.1101/2020.04.01.020966</u>.
- Walls, A C, et al. (2020) Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 181(2), 281-292.e6. <u>https://doi.org/10.1016/j.cell.2020.02.058</u>.

Website: www.torontobioscience.com Brett Wang (Covid-19 Business Development Manager) brett.wang@torontobioscience.com or sales@torontobioscience.com Tel: (+1) 416 417 8573